Tumor heterogeneity and adaptive resistance—such as bypass signaling in BRAF(+) CRC or secondary fusions—underscore the complexity of interpreting agnostic biomarkers into durable treatment tactics [70]. The gene discussed is BRAF; the disease is neoplasm.